Adlai Nortye (NASDAQ:ANL) Director Sells $159,900.00 in Stock

Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Director Ping Ji sold 10,000 shares of the stock in a transaction on Wednesday, September 30th. The shares were sold at an average price of $15.99, for a total value of $159,900.00. Following the transaction, the director directly owned 121,453 shares of the company’s stock, valued at approximately $1,942,033.47. The trade was a 7.61% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Ping Ji also recently made the following trade(s):

• On Tuesday, September 29th, Ping Ji sold 214 shares of Adlai Nortye stock. The shares were sold at an average price of $15.77, for a total value of $3,374.78.
• On Tuesday, September 22nd, Ping Ji sold 5,000 shares of Adlai Nortye stock. The stock was sold at an average price of $16.63, for a total transaction of $83,150.00.

Adlai Nortye Stock Down 1.5%

Shares of NASDAQ ANL traded down $0.23 during mid-day trading on Thursday, reaching $15.77. The company had a trading volume of 9,308 shares, compared to its average volume of 364,887. The stock has a fifty day moving average of $14.23 and a two-hundred day moving average of $12.20. The company has a debt-to-equity ratio of 0.04, a current ratio of 9.55 and a quick ratio of 0.65. Adlai Nortye Ltd. Sponsored ADR has a 12-month low of $0.88 and a 12-month high of $17.25.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on ANL shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Adlai Nortye in a research report on Tuesday, July 14th. Loop Capital set a $49.00 price target on shares of Adlai Nortye in a research report on Tuesday, September 8th. Wall Street Zen cut shares of Adlai Nortye from a “buy” rating to a “hold” rating in a research report on Saturday, September 12th. Cantor Fitzgerald started coverage on Adlai Nortye in a research note on Monday, June 22nd. They issued an “overweight” rating on the stock. Finally, HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of Adlai Nortye in a report on Tuesday, September 8th. Six equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $29.50.

Institutional Investors Weigh In On Adlai Nortye

Hedge funds and other institutional investors have recently made changes to their positions in the business. Braidwell LP bought a new stake in shares of Adlai Nortye during the second quarter worth $9,145,000. Boone Capital Management LLC purchased a new stake in Adlai Nortye in the 2nd quarter valued at about $2,971,000. Seven Fleet Capital Management LP bought a new stake in Adlai Nortye in the second quarter worth about $1,302,000. Affinity Asset Advisors LLC purchased a new stake in Adlai Nortye in the 1st quarter worth about $1,140,000. Finally, ADAR1 Capital Management LLC bought a new stake in shares of Adlai Nortye during the 1st quarter valued at $816,000. 35.21% of the stock is currently owned by institutional investors and hedge funds.

Adlai Nortye Company Profile

Adlai Nortye Ltd. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer and other serious diseases. The company’s research and development activities center on oncology and immuno-oncology, with the goal of addressing unmet needs in the treatment of solid tumors.

Adlai Nortye’s lead candidate is buparlisib, also known as AN2025, an oral pan-class I phosphoinositide 3-kinase (PI3K) inhibitor being developed for oncology indications, including head and neck cancer.